Incyte Corporation (INCY)

Incyte Corporation earns a high AlphaScore of 92/100 in the healthcare sector with a strong buy signal as of October 11, 2026. Key metrics show an exceptional gross margin of 92.76% and a net margin of 25.03%. A major strength is its impressive revenue growth of 21.22%, supported by a robust return on equity of 24.90%. Conversely, a relative risk is its lack of a dividend payout, offering no direct income return for income-focused investors.

Written 11/10/2026, 00:31:13 UTC · Snapshot 11/10/2026